Editorial
Salvage prostate brachytherapy after definitive external radiation: tried and now tested
Abstract
Definitive external beam radiation therapy (EBRT) has long been one of the standard treatment modalities for prostate cancer. However, 15–75% of patients will experience a disease recurrence depending on such factors as the risk group, use and length of androgen deprivation therapy (ADT) and radiation dose (1). Approximately 25% of patients with biochemical recurrence will have local clinical disease progression within 5 years (2).